Viva Biotech Reports 21.3% Net Profit Growth in 2025 Driven by AI and CDMO Expansion

Key Facts

1Viva Biotech's revenue reached RMB 1,729.4 million for the year 2025.

2Net profit recorded a 21.3% year-over-year increase to RMB 269.3 million.

3Gross profit margin improved to 37.9%, representing a 3.3 percentage point increase.

Viva Biotech Holdings (1873.HK) announced its annual financial results for 2025, reporting total revenue of RMB 1,729.4 million. The company's net profit saw a significant year-over-year increase of 21.3%, reaching RMB 269.3 million. Gross profit margin improved by 3.3 percentage points to 37.9%, showcasing enhanced operational efficiency across its business segments. This growth was primarily fueled by the optimization of Langhua Pharmaceutical's business mix and the scaling of CDMO services. Furthermore, the integration of AI-driven drug discovery and improved performance in the CRO sector contributed to the strong financial outcome. These results highlight Viva Biotech's successful transition toward a more technology-intensive and efficient service model in the global biotech market.